Literature DB >> 29431148

Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis.

Nastassya L Chandra1,2, Claire Broad3, Kate Folkard1, Katy Town1, Emma M Harding-Esch1,3,4, Sarah C Woodhall1, John M Saunders1, S Tariq Sadiq1,3,5, J Kevin Dunbar1.   

Abstract

OBJECTIVES: Chlamydia trachomatis is the most commonly diagnosed bacterial STI. Lack of prevalence and risk factor data for rectal chlamydia in women has testing and treatment implications, as azithromycin (a first-line urogenital chlamydia treatment) may be less effective for rectal chlamydia. We conducted a systematic review of studies on women in high-income countries to estimate rectal chlamydia prevalence, concurrency with urogenital chlamydia and associations with reported anal intercourse (AI).
DESIGN: Systematic review and four meta-analyses conducted using random-effects modelling. DATA SOURCES: Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, PsycINFO and the Cochrane Database were searched for articles published between January 1997 and October 2017. ELIGIBILITY CRITERIA: Studies reporting rectal chlamydia positivity in heterosexual women aged ≥15 years old in high-income countries were included. Studies must have used nucleic acid amplification tests and reported both the total number of women tested for rectal chlamydia and the number of rectal chlamydia infections detected. Conference abstracts, case reports and studies with self-reported diagnoses were excluded. Data extracted included setting, rectal and urogenital chlamydia testing results, AI history, and demographics.
RESULTS: Fourteen eligible studies were identified, all among diverse populations attending sexual health services. Among routine clinic-attending women, summary rectal chlamydia positivity was 6.0% (95% CI 3.2% to 8.9%); summary concurrent rectal chlamydia infection was 68.1% in those who tested positive for urogenital chlamydia (95% CI 56.6% to 79.6%); and of those who tested negative for urogenital chlamydia, 2.2% (95% CI 0% to 5.2%) were positive for rectal chlamydia. Reported AI was not associated with rectal chlamydia (summary risk ratio 0.90; 95% CI 0.75 to 1.10).
CONCLUSIONS: High levels of rectal chlamydia infection have been shown in women with urogenital chlamydia infection. The absence of association between reported AI and rectal chlamydia suggests AI is not an adequate indicator for rectal testing. Further work is needed to determine policy and practice for routine rectal testing in women. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  chlamydia trachomatis; meta-analysis; screening; systematic reviews; women

Mesh:

Year:  2018        PMID: 29431148     DOI: 10.1136/sextrans-2017-053161

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  17 in total

1.  Reply to Dukers-Muijrers et al.

Authors:  Christine M Khosropour
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

2.  Antibody, but not B-cell-dependent antigen presentation, plays an essential role in preventing Chlamydia systemic dissemination in mice.

Authors:  Priyangi A Malaviarachchi; Miguel A B Mercado; Stephen J McSorley; Lin-Xi Li
Journal:  Eur J Immunol       Date:  2020-03-12       Impact factor: 5.532

3.  Recurrent/Intermittent Vaginal and Rectal Chlamydial Infection Following Treatment: A Prospective Cohort Study Among Female Sexually Transmitted Disease Clinic Patients.

Authors:  Christine M Khosropour; Olusegun O Soge; Robert Suchland; Gina Leipertz; Anna Unutzer; Rushlenne Pascual; Kevin Hybiske; Lindley A Barbee; Lisa E Manhart; Julia C Dombrowski; Matthew R Golden
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

Review 4.  Trachoma.

Authors:  Anthony W Solomon; Matthew J Burton; Emily W Gower; Emma M Harding-Esch; Catherine E Oldenburg; Hugh R Taylor; Lamine Traoré
Journal:  Nat Rev Dis Primers       Date:  2022-05-26       Impact factor: 52.329

5.  Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  William M Geisler; Jane S Hocking; Toni Darville; Byron E Batteiger; Robert C Brunham
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 9.079

6.  A Web of Complexity: Untangling the Routes of Rectal Chlamydia Acquisition.

Authors:  Christine M Khosropour; Julia C Dombrowski
Journal:  Sex Transm Dis       Date:  2018-08       Impact factor: 2.830

Review 7.  Rectal Chlamydia trachomatis Infection: A Narrative Review of the State of the Science and Research Priorities.

Authors:  Christine M Khosropour; Julia C Dombrowski; Lucia Vojtech; Dorothy L Patton; Lee Ann Campbell; Lindley A Barbee; Michaela C Franzi; Kevin Hybiske
Journal:  Sex Transm Dis       Date:  2021-12-01       Impact factor: 2.830

8.  Detection of Rectal Chlamydia trachomatis in Heterosexual Men Who Report Cunnilingus.

Authors:  Teresa A Batteiger; Stephen J Jordan; Evelyn Toh; Lora Fortenberry; James A Williams; Michelle LaPradd; Barry Katz; J Dennis Fortenberry; Brian Dodge; Janet Arno; Byron E Batteiger; David E Nelson
Journal:  Sex Transm Dis       Date:  2019-07       Impact factor: 3.868

9.  Chlamydia muridarum Genital and Gastrointestinal Infection Tropism Is Mediated by Distinct Chromosomal Factors.

Authors:  Sandra G Morrison; Amanda M Giebel; Evelyn C Toh; Horace J Spencer; David E Nelson; Richard P Morrison
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

10.  Chlamydiae in human intestinal biopsy samples.

Authors:  Nicole Borel; Hanna Marti; Andreas Pospischil; Theresa Pesch; Barbara Prähauser; Sabina Wunderlin; Helena M B Seth-Smith; Nicola Low; Renata Flury
Journal:  Pathog Dis       Date:  2018-11-01       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.